Novavax's COVID vaccine rollout in EU off to a slow start – data

By Reuters

Demand for the COVID-19 vaccine produced by U.S. biotech firm Novavax has been underwhelming in the European Union's main countries in the early rollout, so far undermining hopes that it could convince vaccine sceptics to get a shot. The Novavax vaccine, the latest to receive the EU regulators' approval under the trade name of Nuvaxovid, was expected to persuade some sceptics because it is based on a more conventional technology than the other four vaccines authorised so far in the EU. But initial data on Nuvaxovid's rollout show that it has had a small impact on vaccination campaigns.

…read more

Via:: Sports Headlines

      

Get 20% off hat purchases for ONLY $5! Join our LIDS Club @ lids.com.
%d bloggers like this: